Activity Dates: 04/21/2009 - 04/21/2012
This course is closed. Please look for other available products in CPNP University.
If you are a pharmacist, nurse practitioner or other healthcare professional involved in the comprehensive medication management of psychiatric and/or neurological patients, we invite you to participate in this online course.
Bipolar disorder affects approximately 1% of the worldwide population. Several pharmacologic options are available to treat this condition and treatment guidelines are available to direct treatment. Common treatment guidelines in the United States include the American Psychiatric Association guidelines, the Expert Consensus Guidelines, and the Texas Implementation of Medical Algorithms for Bipolar Disorder treatment algorithm, while European guidelines include the European Collegeof Neuropsychopharmacology (ECNP) Consensus Statement on Bipolar Disorder and the National Institute for Health and Clinical Excellence (NICE) guidelines.
Although similarities exist between the U.S. And European guidelines, several key differences are also apparent. or example, carbamazepine is considered a second-line option for the treatment of mania or hypomania in the US, while the NICE guidelines advise against the routine use of carbamazepine in Europe. In the US, lamotrigine is recommended as a potential first-line option for treatment of acute bipolar depression, while the NICE guidelines state that lamotrigine should not be used as a single, first-line agent. Finally, the US guidelines support that use of risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole as potential first or second-line options for the treatment of manic/hypomanic episodes while the NICE guidelines only routinely recommend the use of risperidone, olanzapine, and quetiapine. In this session, evidence supporting each country's recommendations will be presented and debated in a point-counterpoint format.
You will proceed through the following steps to satisfactorily complete this course:
This course is provided online at cpnp.org and consists of the speaker audio and slides. A PDF file of the slides is also provided and access is available to participants indefinitely although ACPE credit is available only through the course expiration date.
Participants in this course must complete an examination and achieve a score of 60% or greater. Successful completion of the course also requires the completion of a course evaluation. ACPE statements of credit can be retrieved by participants online at cpnp.org immediately upon successful completion of the course.
CPNP has invested in supporting the most popular web browsers and leveraging software that our members use daily. Beyond PDF downloads, the rest of the system is built on HTML5, a technology that most up-to-date browsers will support. To access CPNP course materials online, you will need:
CPNP web sites no longer fully support Microsoft Internet Explorer 9 and older or Windows Vista and older. We cannot guarantee that the site will function perfectly on every device and configuration, but using the latest version of the software above will greatly improve your experience.
Charles L. Bowden, MD
Heinz C.R. Grunze, MD,PHD
The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This self-study course provides 2.0 contact hours (0.2 CEUs) of knowledge-based continuing education credit from CPNP approved programming. The ACPE universal program number assigned to this course is 0284-0000-09-009-H01-P (2.0 contact hours).
ACPE approved contact hours are accepted for ANCC Certification Renewal (see pages 5 and 6): At least 50% (37.5 hours) of your 75 continuing education hours must be formally approved continuing education hours. Formally approved continuing education hours meet one or more of the criteria listed below:
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information and disclosures). The opinions expressed in the educational activity do not necessarily represent the views of CPNP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Presentation-Specific Disclosure: Grunze (Amisulpride, Clozapine)
This programming was supported in part by grants from Bristol-Myers Squibb, Forest Laboratories, Inc., Lilly, Schering-Plough, Cyberonics, and Shire.